Want to join the conversation?
$ESRX's 3Q15 adjusted EBITDA increased 4% year-over-year as a result of managing specialty, formulary management and an increase in the aggregate generic fill rate. Adjusted SG&A expenses increased 2% year-over-year. Adjusted EBITDA per claim was $5.51, an increase of 4% year-over-year. $ESRX deployed approx. $1.2Bil of cash to repay debt in 3Q15.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?